Orphan drug companies have used with tremendous success as part of their drug life cycle management, the strategy to extend the life of their product by devising a succession of multiple discrete indications for the orphan drug. 577 more words
Tags » Gleevec
This is the third Blog Post in a series that presents books in the rare disease and orphan drug space.
IUPAC Name:- 4-[(4-Methyl-1-piperazinyl)methyl]-N-amino]phenyl]benzamide
M. P.:- 211-213 °C